RXRX Stock Price Today (May 2026) — Recursion Pharmaceuticals, Inc. Analysis & Key Metrics 2026-05-22
Recursion Pharmaceuticals, Inc. (RXRX) is trading at $3.01, down 3.22% today (as of May 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $6.57 (118.3% upside).
- Volatility remains elevated (44.12% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.82% YoY) alongside significant competitive pressures.
RXRX Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
Recursion Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $1.19B
P/E Ratio
Forward P/E: -3.85
Revenue Growth
Year over Year
Analyst Target
+118.3% upside potential
Key Investor Questions About RXRX
What investors need to know before buying
Based on current market data, RXRX presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 41.61)
- Fundamentals say: Caution warranted (high leverage concerns)
RXRX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for RXRX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $77.97M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, RXRX stock traded between $2.80 and $7.18—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 44.12% annualized volatility and β=1.05, the stock exhibits moderate correlation to market moves—making RXRX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth Prospects
Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past three months. See our latest analysis for Recursion Pharmaceuticals. Recent trading has been choppy, with the 1 day share price return down 3.22% and the 30 day share price return down 14.24%, while the 1 year total shareholder return has declined 26.23%. This may indicate fading momentum as...
Morgan Stanley Raises its Price Target on Recursion (RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 14, 2026, Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $5.50 from $5 and kept an Equal Weight rating on the shares. On May 6, 2026, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported […]
A Deep Dive Into NVIDIA’s Latest Portfolio Moves
NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now
With a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst consensus estimates of $15.78 million. The company ended the quarter with approximately $665.2 million in cash, cash equivalents, and restricted cash, […]
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA Discussions
Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away from a mixed quarterly earnings print. See our latest analysis for Recursion Pharmaceuticals. At a share price of US$3.27, Recursion’s 30 day share price return of 2.51% sits against a 90 day share price decline of 17.84% and a 1 year total shareholder return of 25.51% loss. This suggests that...
Recursion Milestones Link AI Discovery To Clinical And Valuation Upside
Recursion Pharmaceuticals (NasdaqGS:RXRX) reported key clinical milestones across its AI-driven pipeline, including positive early data for REC-1245. The company initiated a new Phase 1 trial for REC-4539, expanding its early-stage clinical portfolio. REC-4881 achieved Phase 2 success in familial adenomatous polyposis, with active FDA engagement around a potential registrational pathway. Recursion Pharmaceuticals focuses on applying AI-driven drug discovery to build a diversified clinical...
3 Stocks Poised to Disrupt the Healthcare Market by 2030
The old healthcare model is breaking down.
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
Recursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right Now
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 2026, highlighted by positive early data for its RBM39 degrader, REC-1245. In the Phase 1/2 DAHLIA study, the molecule showed a well-tolerated safety profile […]
Recursion (RXRX) Q1 2026 Earnings Transcript
Najat Khan: Good morning, everyone, and thank you for joining us. First, we're focusing on signal over noise, generating proof and proof points across our both wholly owned programs and our partner programs with the goal to showcase where AI can truly make a difference in creating value.
Frequently Asked Questions
Common investor questions about Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is currently trading at $3.01. The RSI (14-day) is at 41.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $6.57 implies 118.3% upside from current levels. Volatility is high at 44.1% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Recursion Pharmaceuticals, Inc. (RXRX): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is -3.85. Price-to-Book is 1.64. Price-to-Sales is 25.01. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 7 analysts covering RXRX, the consensus price target is $6.57. This represents a 118.3% upside from the current price of $3.01. The range spans from a low target of $3.00 to a high target of $10.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Recursion Pharmaceuticals, Inc. (RXRX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Recursion Pharmaceuticals, Inc. (RXRX) investors include: 1. High volatility (44.1% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Elevated short interest (34.9% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Recursion Pharmaceuticals, Inc.'s (RXRX) current debt and financial health profile: Total debt stands at $77.97M. The debt-to-equity ratio is 6.89, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 5.50, indicating strong short-term liquidity. The quick ratio is 5.20. The company holds $743.29M in cash and equivalents. Free cash flow is negative at $-208,521,744, which could limit the company's ability to manage debt obligations.